{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:20:07Z","timestamp":1793319607867,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-000013"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-000013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007491"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007491"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/00709\/2019"],"award-info":[{"award-number":["UID\/Multi\/00709\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejphar.2020.173554","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T22:06:25Z","timestamp":1600121185000},"page":"173554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":508,"special_numbering":"C","title":["Alzheimer's disease: Recent treatment strategies"],"prefix":"10.1016","volume":"887","author":[{"given":"Miguel","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173554_bib1","first-page":"149","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild alzheimer's disease suggest disease modification potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib2","first-page":"219","article-title":"Clinical benefits of tramiprosate in alzheimer's disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect\u201d","volume":"3","author":"Abushakra","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: understanding the Alzheimer's disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ejphar.2020.173554_bib5","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1074\/jbc.RA119.012517","article-title":"Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau","volume":"295","author":"Ait-Bouziad","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2020.173554_bib6","first-page":"391","article-title":"2020 Alzheimer's disease facts and figures","author":"Alzheimer\u2019s Association","year":"2020","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2020.173554_bib7","series-title":"World Alzheimer Report 2019: Attitudes to Dementia","author":"Alzheimer\u2019s Disease International","year":"2019"},{"key":"10.1016\/j.ejphar.2020.173554_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005917","article-title":"Stabilization of microtubule-unbound Tau via Tau phosphorylation at Ser262\/356 by Par-1\/MARK contributes to augmentation of AD-related phosphorylation and a\u03b242-induced Tau toxicity","volume":"12","author":"Ando","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejphar.2020.173554_bib9","first-page":"104","article-title":"Microdose lithium treatment stabilized cognitive impairment in patients with alzheimer's disease","volume":"10","author":"Andrade Nunes","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2020.173554_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098153","article-title":"First administration of the Fc-attenuated anti-\u03b2 amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study","volume":"10","author":"Andreasen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2020.173554_bib11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate alzheimer's disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2020.173554_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2020.173554_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in alzheimer's disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib14","author":"Axon Neuroscience"},{"key":"10.1016\/j.ejphar.2020.173554_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173554_bib16","article-title":"Role of tau as a microtubule-associated protein: structural and functional aspects","volume":"10","author":"Barbier","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib17","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1523\/JNEUROSCI.0188-12.2012","article-title":"Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027","volume":"32","author":"Barten","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science (80-. )"},{"key":"10.1016\/j.ejphar.2020.173554_bib19","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.173554_bib20","author":"Biogen"},{"key":"10.1016\/j.ejphar.2020.173554_bib21","author":"Biogen"},{"key":"10.1016\/j.ejphar.2020.173554_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib23","series-title":"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring","author":"Bowman-Rogers","year":"2017"},{"key":"10.1016\/j.ejphar.2020.173554_bib24","series-title":"Picking through the Rubble , Field Tries to Salvage BACE Inhibitors","author":"Bowman Rogers","year":"2019"},{"key":"10.1016\/j.ejphar.2020.173554_bib25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and Ab imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib27","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's disease","volume":"55","author":"Cebers","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/tra.12537","article-title":"Tau directs intracellular trafficking by regulating the forces exerted by kinesin and dynein teams","volume":"19","author":"Chaudhary","year":"2018","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2020.173554_bib30","article-title":"Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2020.173554_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00659","article-title":"Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","article-title":"Tau PET in Alzheimer disease and mild cognitive impairment","volume":"87","author":"Cho","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.173554_bib33","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib54","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib55","doi-asserted-by":"crossref","first-page":"E1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.173554_bib56","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's Disease","volume":"308","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173554_bib57","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for alzheimer's disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of alzheimer's disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173554_bib59","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2147\/NDT.S106479","article-title":"A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts","volume":"12","author":"Dell'Osso","year":"2016","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2020.173554_bib60","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in alzheimer's disease mice","volume":"76","author":"DeMattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2020.173554_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"Deture","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2020.173554_bib62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2020.173554_bib65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib66","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib67","author":"Eisai"},{"key":"10.1016\/j.ejphar.2020.173554_bib68","author":"Eisai"},{"key":"10.1016\/j.ejphar.2020.173554_bib69","article-title":"Microglia and astrocytes in Alzheimer's disease: implications for therapy","volume":"15","author":"Fakhoury","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2020.173554_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib71","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","article-title":"Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology","volume":"85","author":"Fenili","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.173554_bib74","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.25011\/cim.v42i1.32393","article-title":"Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: a systematic review and network meta-analysis","volume":"42","author":"Foroutan","year":"2019","journal-title":"Clin. Investig. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14283\/jpad.2019.12","article-title":"Combination therapy for alzheimer's disease: perspectives of the EU\/US CTAD task force","volume":"6","author":"Gauthier","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib76","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173554_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer's disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2020.173554_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13311-014-0313-y","article-title":"\u03b2-Amyloid peptides and amyloid plaques in alzheimer's disease","volume":"12","author":"Gouras","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2020.173554_bib79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fnmol.2018.00151","article-title":"ADNP, a microtubule interacting protein, provides neuroprotection through end binding proteins and Tau: an amplifier effect","volume":"11","author":"Gozes","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib80","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.3390\/ijms21124214","article-title":"Pleiotropic role of Notch signaling in human skin diseases","volume":"21","author":"Gratton","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.173554_bib81","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline","volume":"302","author":"Green","year":"2010","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2020.173554_bib82","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.3233\/JAD-179935","article-title":"Role of amyloid-\u03b2 and tau proteins in alzheimer's disease: confuting the amyloid cascade","volume":"64","author":"Gulisano","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib83","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173554_bib84","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-190197","article-title":"Lithium as a treatment for alzheimer's disease: the systems pharmacology perspective","volume":"69","author":"Hampel","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib85","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3233\/JAD-151206","article-title":"A theoretical analysis of the synergy of amyloid and tau in alzheimer's disease","volume":"52","author":"Han","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib86","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer's disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2020.173554_bib87","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173554_bib88","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib89","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of alzheimer's disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2020.173554_bib90","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41582-019-0295-9","article-title":"Questions EMERGE as Biogen claims aducanumab turnaround","volume":"16","author":"Howard","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib92","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate alzheimer's disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2020.173554_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00261","article-title":"Pharmacotherapy of alzheimer's disease: seeking clarity in a time of uncertainty","volume":"11","author":"Husna Ibrahim","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173554_bib94","author":"ISRCTN"},{"key":"10.1016\/j.ejphar.2020.173554_bib95","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/mp.2016.255","article-title":"ADNP\/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy","volume":"22","author":"Ivashko-Pachima","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173554_bib96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14283\/jpad.2019.18","article-title":"Commentary: combination therapy for alzheimer's disease - the next step","volume":"6","author":"Jessen","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib97","first-page":"1","article-title":"Cognitive symptoms of Alzheimer's disease: clinical management and prevention","volume":"367","author":"Joe","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2020.173554_bib98","article-title":"Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"Joie","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS b-Amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib101","first-page":"192","article-title":"A randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with QS-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate alzheimer's disease","volume":"3","author":"Ketter","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2 40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase i trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib104","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejphar.2020.173554_bib107","doi-asserted-by":"crossref","DOI":"10.1186\/alzrt249","article-title":"Modulation of \u03b2-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase i study","volume":"6","author":"Leyhe","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib108","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173554_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173554_bib111","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.trci.2019.02.005","article-title":"The Alzheimer's Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease","volume":"5","author":"Lopez Lopez","year":"2019","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/YCO.0000000000000587","article-title":"Passive antiamyloid immunotherapy for Alzheimer\u02bcs disease","volume":"33","author":"Loureiro","year":"2020","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173554_bib113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib114","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/gps.1964","article-title":"A feasibility and tolerability study of lithium in Alzheimer's disease","volume":"23","author":"Macdonald","year":"2008","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejphar.2020.173554_bib115","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","article-title":"The amyloid hypothesis on trial","volume":"559","author":"Makin","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173554_bib116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.018","article-title":"Pivotal role of glycogen synthase kinase-3: a therapeutic target for Alzheimer's disease","volume":"107","author":"Maqbool","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173554_bib117","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2020.173554_bib118","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-190256","article-title":"Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer's disease: a systematic review and meta-analysis","volume":"69","author":"Matsunaga","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib119","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for alzheimer's disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2020.173554_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2020.173554_bib122","doi-asserted-by":"crossref","first-page":"E1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.173554_bib123","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm1423","article-title":"Cyclohexanehexol inhibitors of A\u03b2 aggregation prevent and reverse Alzheimer phenotype in a mouse model","volume":"12","author":"McLaurin","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib124","first-page":"1","article-title":"Memantine for dementia","volume":"2019","author":"McShane","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2020.173554_bib125","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.peptides.2010.04.011","article-title":"NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-A microtubule-deficient model of schizophrenia","volume":"31","author":"Merenlender-Wagner","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2020.173554_bib126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.ejphar.2020.173554_bib127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.14283\/jpad.2019.15","article-title":"Editorial: is now the time for combination therapies for alzheimer disease?","volume":"6","author":"Morris","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194661","article-title":"The role of protein misfolding and tau oligomers (TauOs) in Alzheimer's disease (AD)","volume":"20","author":"Mroczko","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.173554_bib129","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2020.173554_bib130","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer's disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.173554_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00798","article-title":"Ten years of tau-targeted immunotherapy: the path walked and the roads ahead","volume":"12","author":"Novak","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14283\/jpad.2018.45","article-title":"AADvac1, an active immunotherapy for alzheimer's disease and non alzheimer tauopathies: an overview of preclinical and clinical development","volume":"6","author":"Novak","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib136","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.173554_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib138","article-title":"Clinical trials in alzheimer's disease: a hurdle in the path of remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib139","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","article-title":"BACE inhibitors in clinical development for the treatment of Alzheimer's disease","volume":"18","author":"Panza","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejphar.2020.173554_bib140","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/imt-2016-0019","article-title":"Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy","volume":"8","author":"Panza","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejphar.2020.173554_bib141","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.celrep.2018.12.085","article-title":"Microtubules deform the nuclear membrane and disrupt nucleocytoplasmic transport in tau-mediated frontotemporal dementia","volume":"26","author":"Paonessa","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2020.173554_bib142","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer's disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib143","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer's disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071659","article-title":"Oligomerization and conformational change turn monomeric \u03b2-amyloid and tau proteins toxic: their role in Alzheimer's pathogenesis","volume":"25","author":"Penke","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2020.173554_bib145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-\u03b2 immunotherapy in alzheimer's disease: a systematic review and meta-analysis","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173554_bib146","doi-asserted-by":"crossref","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer's disease","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib147","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib148","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-160965","article-title":"A randomized, double-blind, placebo-controlled, phase II study of oral ELND005 (scyllo -inositol) in young adults with down syndrome without dementia","volume":"58","author":"Rafii","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib149","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/dvdy.24599","article-title":"ReMAPping the microtubule landscape: how phosphorylation dictates the activities of microtubule-associated proteins","volume":"247","author":"Ramkumar","year":"2018","journal-title":"Dev. Dynam."},{"key":"10.1016\/j.ejphar.2020.173554_bib150","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in alzheimer's disease: it's time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2020.173554_bib151","author":"Roche"},{"key":"10.1016\/j.ejphar.2020.173554_bib152","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2174\/1567205015666180821114813","article-title":"Long-term safety and efficacy of bapineuzumab in patients with mild-to- moderate alzheimer\u2019 s disease: a phase 2, open-label extension study","volume":"15","author":"Salloway","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2020.173554_bib153","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib154","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2020.173554_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173554_bib156","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ejmech.2017.11.103","article-title":"Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions","volume":"144","author":"Saraswati","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173554_bib157","first-page":"103","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE\u00ae AD02 in patients with early alzheimer's disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib158","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer's disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib159","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-141725","article-title":"Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort","volume":"44","author":"Seeburger","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib161","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2020.173554_bib162","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3\u03b2 inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib163","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173554_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2017.00083","article-title":"Tau oligomers: cytotoxicity, propagation, and mitochondrial damage","volume":"9","author":"Shafiei","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib165","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau immunotherapies for alzheimer's disease and related tauopathies: progress and potential pitfalls","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib166","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000440842","article-title":"Tau immunotherapy","volume":"16","author":"Sigurdsson","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib167","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the alzheimer's association research roundtable workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2020.173554_bib168","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(89)92246-0","article-title":"Long-term hepatotoxicity of tacrine","volume":"333","author":"Summers","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173554_bib169","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","article-title":"Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age","volume":"72","author":"Sutphen","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2020.173554_bib171","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.trci.2016.08.001","article-title":"Profiling the dynamics of CSF and plasma A\u03b2 reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor","volume":"2","author":"Timmers","year":"2016","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib172","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/brain\/awx046","article-title":"Association between tau deposition and antecedent amyloid-\u03b2 accumulation rates in normal and early symptomatic individuals","volume":"140","author":"Tosun","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.173554_bib173","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating alzheimer's disease: systematic review and network metaanalysis","volume":"66","author":"Tricco","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejphar.2020.173554_bib174","author":"United Neuroscience"},{"key":"10.1016\/j.ejphar.2020.173554_bib175","first-page":"75","article-title":"Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early alzheimer's disease: amyloid imaging positron emission tomography and safety results from a phase 2 study","volume":"3","author":"van Dyck","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib177","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer's disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib178","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fncel.2018.00226","article-title":"Repositioning microtubule stabilizing drugs for brain disorders","volume":"12","author":"Varidaki","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib179","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ijbiomac.2019.04.120","article-title":"Regulation of neuronal microtubule dynamics by tau: implications for tauopathies","volume":"133","author":"Venkatramani","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejphar.2020.173554_bib180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","article-title":"UB-311, a novel UBITh\u00ae amyloid \u03b2 peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejphar.2020.173554_bib181","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib182","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s12035-015-9143-0","article-title":"The essential role of soluble A\u03b2 oligomers in alzheimer's disease","volume":"53","author":"Wang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2020.173554_bib183","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"46285","author":"Wessels","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib184","first-page":"236","article-title":"Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of alzheimer's disease and other tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib185","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib186","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib187","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib188","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer's disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2020.173554_bib189","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2020.173554_bib190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2020.173554_bib191","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/jnen\/nly059","article-title":"\u03b2-amyloid induces pathology-related patterns of tau hyperphosphorylation at synaptic terminals","volume":"77","author":"Wu","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib192","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neulet.2019.02.011","article-title":"\u03b3-Secretase and its modulators: twenty years and beyond","volume":"701","author":"Xia","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2020.173554_bib193","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0813-8","article-title":"Structural basis of Notch recognition by human \u03b3-secretase","volume":"565","author":"Yang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173554_bib194","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.25513","article-title":"Target engagement in an alzheimer trial: crenezumab lowers amyloid \u03b2 oligomers in cerebrospinal fluid","volume":"86","author":"Yang","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2020.173554_bib195","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1523\/JNEUROSCI.4922-11.2012","article-title":"The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and alzheimer-like pathology in an interventional study with aged tau transgenic mice","volume":"32","author":"Zhang","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173554_bib196","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer's disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:42:59Z","timestamp":1757976179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":176,"alternative-id":["S0014299920306464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173554","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease: Recent treatment strategies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173554"}}